Looking at how adults with newly diagnosed B-cell lymphoma are treated
Reviews past records of untreated adults with diffuse large B-cell lymphoma starting first treatment.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate Treatment Patterns and Investigate Adult Patients With B-cell Lymphoma
Key facts
- Where
- Campinas, Curitiba, and São Paulo, BrazilSee the 5 sites
Where in Brazil
- UNICAMPCampinas, BrazilNo longer taking part
- Hospital Erasto GaertnerCuritiba, BrazilNo longer taking part
- AC Camargo Cancer CenterSão Paulo, BrazilNo longer taking part
- Hospital Israelita Albert EinsteinSão Paulo, BrazilNo longer taking part
- Hospital Municipal da Vila Santa CatarinaSão Paulo, BrazilNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07882576
- Record updated
- 20 October 2026
- Original description
This is a retrospective observational registry study designed to characterise patient profiles, assess treatment patterns, evaluate clinical outcomes and explore COO testing patterns among adult patients with newly diagnosed LDGCB who have not previously received treatment (TN) and are receiving first-line (1L) treatment.Read full original descriptionShow less
WW-CLARITY: Real-world Characteristics, Treatments, and Outcomes of Treatment-Naïve (TN) Patients With Diffuse Large B- Cell Lymphoma (DLBCL) in the UK, France, Canada, and Brazil
This is a retrospective observational registry study designed to characterise patient profiles, assess treatment patterns, evaluate clinical outcomes and explore COO testing patterns among adult patients with newly diagnosed LDGCB who have not previously received treatment (TN) and are receiving first-line (1L) treatment.
Inclusion: Patients with newly diagnosed LDGCB prior to the index date during the study identification period (1 January 2020 to 1 July 2024) in registries/databases in Brazil, Canada, France and the United Kingdom; Patients aged ≥ 18 years at the time of their first diagnosis of LDGCB; Patients who started eligible first-line systemic therapy during the study identification period (1 January 2020 to 1 July 2024); Identify patients who started palliative care during the study identification period (1 January 2020 to 31 December 2024).
Exclusion: Patients who were treated for another primary cancer diagnosis documented less than 5 years prior to the index event; Patients who received systemic treatment for LDGCB prior to the index event; Patients who received palliative care as first-line treatment; Patients who participated in a clinical trial after the index date (i.e. who received treatment for LDGCB as part of a clinical trial).